MY156913A - Oral administration of peripherally-acting opioid antagonists - Google Patents

Oral administration of peripherally-acting opioid antagonists

Info

Publication number
MY156913A
MY156913A MYPI2010005212A MYPI20105212A MY156913A MY 156913 A MY156913 A MY 156913A MY PI2010005212 A MYPI2010005212 A MY PI2010005212A MY PI20105212 A MYPI20105212 A MY PI20105212A MY 156913 A MY156913 A MY 156913A
Authority
MY
Malaysia
Prior art keywords
peripherally
oral administration
opioid antagonists
acting opioid
acting
Prior art date
Application number
MYPI2010005212A
Other languages
English (en)
Inventor
Kevin J Brodbeck
Alan R Kugler
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MY156913A publication Critical patent/MY156913A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MYPI2010005212A 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists MY156913A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07

Publications (1)

Publication Number Publication Date
MY156913A true MY156913A (en) 2016-04-15

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2010005212A MY156913A (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Country Status (15)

Country Link
US (1) US20110160239A1 (enExample)
EP (1) EP2300009A1 (enExample)
JP (1) JP2011519930A (enExample)
KR (1) KR20110004425A (enExample)
CN (1) CN102014907A (enExample)
AU (1) AU2009244805B2 (enExample)
BR (1) BRPI0912219A2 (enExample)
CA (1) CA2723685C (enExample)
EA (1) EA201001643A1 (enExample)
IL (1) IL208794A0 (enExample)
MX (1) MX2010011727A (enExample)
MY (1) MY156913A (enExample)
NZ (1) NZ589733A (enExample)
WO (1) WO2009137086A1 (enExample)
ZA (1) ZA201007531B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
EA029096B1 (ru) * 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
PE20140636A1 (es) 2010-09-30 2014-06-18 Astrazeneca Ab Conjugado de naloxol-peg cristalino
AU2012359013A1 (en) * 2011-12-19 2014-06-26 Salix Pharmaceuticals, Ltd. Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
HUE036084T2 (hu) 2014-04-28 2018-06-28 Orphomed Inc Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
CN107406456B (zh) * 2015-12-01 2019-08-30 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
PT1225897E (pt) * 1999-11-01 2005-01-31 John Rhodes Composicao para o tratamento da obstipacao e do sindroma do intestino irritavel
EP2236161A1 (en) * 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
HRP20140361T1 (hr) * 2003-12-16 2014-05-23 Nektar Therapeutics Monodisperzne smjese pegiliranog naloksola
MX2008013594A (es) * 2006-04-21 2009-01-16 Nektar Therapeutics Al Corp Reduccion estereoselectiva de una morfinona.
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与

Also Published As

Publication number Publication date
AU2009244805B2 (en) 2013-01-10
CA2723685A1 (en) 2009-11-12
US20110160239A1 (en) 2011-06-30
KR20110004425A (ko) 2011-01-13
EA201001643A1 (ru) 2011-06-30
CA2723685C (en) 2016-09-27
AU2009244805A1 (en) 2009-11-12
WO2009137086A1 (en) 2009-11-12
NZ589733A (en) 2012-07-27
MX2010011727A (es) 2010-11-30
ZA201007531B (en) 2012-03-28
BRPI0912219A2 (pt) 2015-10-06
EP2300009A1 (en) 2011-03-30
JP2011519930A (ja) 2011-07-14
IL208794A0 (en) 2010-12-30
CN102014907A (zh) 2011-04-13

Similar Documents

Publication Publication Date Title
EA201001643A1 (ru) Пероральное введение периферически действующих опиоидных антагонистов
GB0807605D0 (en) Lipid composition
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
AU2011328497A8 (en) Dosing regimen for sedation with CNS 7056 (remimazolam)
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
IL216159A (en) Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication
ZA201100615B (en) Appetising medicament for oral administration in solid form
MX2009011473A (es) Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
UA115139C2 (uk) Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту
EA201490304A1 (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
MY149731A (en) Compounds
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TW200744568A (en) Epinephrine dosing regimens
MX2009010977A (es) Metodos de administracion de tetrahidrobiopterina, composiciones asociadas y metodos de medicion.
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MY189329A (en) Mixture of non-digestible oligosaccharides for stimulating the immune system
MY152279A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009003518A (es) Uso de antagonistas de tgf-beta para tratar a los infantes en riesgo de desarrollar displasia brocopulmonar.
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX339470B (es) Formulacion que contiene nicotina.
MX2015007678A (es) Liberacion transmucosa de acetato de glatiramero por medio de tabletas orales.
MX352997B (es) Derivados de espirotienopiran-piperidina como antagonistas del receptor orl-1 para su uso en el tratamiento de dependencia y abuso de alcohol.